New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 13, 2017 – The FDA announced the approval of Ifixi (infliximab-qbtx), Pfizer’s biosimilar to Janssen Biotech’s Remicade® (infliximab).
Download PDF
Return to publications
